[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Vienna\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":319},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,51,86,118,160,181,206,229,247,264,295],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641903","an-ecological-momentary-intervention-for-the-reduction-of-impairment-in-somatic-symptom-disorder-100641903",false,"NCT07646509","An Ecological Momentary Intervention for the Reduction of Impairment in Somatic Symptom Disorder","Inclusion Criteria:\n\n* Somatic Symptom Disorder\n\nExclusion Criteria:\n\n* chronic physical illnesses that fully explain the somatic symptoms\n* current psychotic disorder\n* current bipolar disorder\n* current self-harming behavior\n* current suicidality\n* current psychotherapy\n* alcohol, drug, or medication dependence within the past 6 months","ALL","18 Years","65 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Persistent somatic symptoms significantly impair the daily lives of individuals with Somatic Symptom Disorder (SSD). Negative psychological factors (NPFs), such as catastrophizing and negative affectivity, further compound this impairment. Yet, few studies have examined strategies in daily life that directly target somatic symptoms and their dynamic relationship with NPFs. The goal of this clinical trial is to investigate if an Ecological Momentary Intervention (EMI) using music listening and cognitive reappraisal can reduce the intensity of and impairment due to somatic symptoms in 40 individuals with Somatic Symptom Disorder (SSD), aged 18-65 years.\n\nParticipants will report symptom intensity, impairment, and NPFs up to four times daily via a smartphone app over a six-week period. Using an intraindividual randomized controlled design, during weeks two to five, participants will be randomly assigned in the ratio of 50:25:25 to no intervention, music listening, and cognitive reappraisal, both at fixed times (evening measurement) and during episodes of acute somatic impairment.",[26,27,28,29,30],"Somatic Symptom Disorder (DSM-5)","Impairment","Psychological Factors","Persistent Physical Symptoms","Medically Unexplained Symptoms",[32,33,34,35,36,37],"Ecological Momentary Intervention","Persistent Somatic Symptoms","Daily Life","Music","Cognitive reappraisal","Somatic Symptom disorder","RECRUITING","2026-06-09",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2025-06-26",{"date":46,"type":20},"2026-10",{"name":48,"class":49},"University of Vienna","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":17,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":50},"100556603","nitrate-exercise-and-vascular-function-in-midlife-women-100556603","NCT06527248","Nitrate, Exercise and Vascular Function in Midlife Women","Effects of Dietary Nitrate From Beetroot Juice on Vascular Function and Adaptations to Exercise Training in Postmenopausal Women: a Randomized, Placebo-controlled Study","Women's-Beet","Inclusion Criteria:\n\n* Postmenopausal women (amenorrhoeic ≥1 year), between the ages of 45 and 65 years, inclusive, who are either normotensive or are medically treated for stage 1 hypertension\n* Written informed consent\n\nExclusion Criteria:\n\n* Current or recent (within previous 3 months) engagement in exercise training (i.e., planned, structured, and regular exercise) with an average net exercise time of \\>2 hours per week\n* Above-average cardiorespiratory fitness levels (i.e., a V̇O2 max max above the 75th percentile of age- and sex-specific normative data: ≥43 mL\u002Fkg\u002Fmin for women aged 45-49 years, ≥38 mL\u002Fkg\u002Fmin for women aged 50-59 years, ≥35 mL\u002Fkg\u002Fmin for women aged 60-65 years)\n* Any evidence of acute or chronic diseases such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) \\\u003C50 mL\u002Fmin), pulmonary, neural, or musculoskeletal disease, osteoporotic fractures, cancer, or type 1 or 2 diabetes mellitus\n* Fasting glucose \\>7.0 mmol\u002FL or HbA1c \\> 6.5 rel. %\n* BMI \\\u003C18.5 kg\u002Fm2 or \\>30kg\u002Fm2\n* A mean 24-hour ambulatory systolic\u002Fdiastolic blood pressure of ≥130\u002F80 mm Hg\n* Irregular resting electrocardiography (ECG)\n* Inability to perform physical exercise\n* Abnormal cardiovascular responses during the baseline V ̇O2 max test, including symptoms, ECG abnormalities, arrhythmias, or exaggerated blood pressure responses\n* Current or recent (\\\u003C12 months) oestrogen-based hormone-replacement therapy\n* Chronic use of nitric oxide (NO) donors, organic nitrites\u002Fnitrates, Ticagrelor, sodium-glucose cotransporter 2 (SGLT2) inhibitors, high-dose statins (i.e., Simvastatin \\>40mg\u002Fday, Atorvastatin \\>20mg\u002Fday, Rosuvastatin \\>10mg\u002Fday), acetylsalicylic acid \\>100mg\u002Fday, non-steroidal anti-inflammatory drugs (NSAID)\n* A change in drug therapy likely to influence major outcomes within the previous 2 months, or likelihood that drug therapy would change during the study\n* Use of antibiotics (within previous 2 months)\n* Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouthwash for a period of 4 weeks before randomization will be included)\n* Being vegan or vegetarian or consumption of \\>5 serves of vegetables per day\n* Current or recent (within previous 6 months) significant (\\>6%) loss or gain of body weight\n* Current or recent (\\\u003C12 months) regular smoking of \\>5 cigarettes per day\n* Alcohol intake of \\>70 g per week and\u002For binge drinking behaviour\n* Inability or unwillingness to follow the study protocol",true,"FEMALE","45 Years",{"count":63,"type":20},54,[23],"The purpose of this clinical study in women after menopause is to investigate whether the daily intake of nitrate from beetroot juice over 12 weeks enhances the positive effect of exercise training on vascular function, blood pressure and physical performance.\n\nThe risk of cardiovascular diseases (CVD) increases with advancing age and women are particularly affected. In women, the decline in the sex hormone oestrogen in the blood circulation with menopause contributes to impaired vascular function and an increased CVD risk; in part through increased inflammatory processes, oxidative stress, and a reduced body's own production of nitric oxide (NO). NO is a signaling molecule that is important for vascular function. Endurance-based exercise training is a key lifestyle strategy to prevent CVD. However, studies indicate that exercise is less effective in terms of its health-promoting adaptations in women after menopause as compared with men of similar age.\n\nThis study investigates the effect of exercise training in combination with the intake of nitrate-rich beetroot juice on functions of the cardiovascular system. Nitrate is a nitrogen compound that is found naturally in plant foods (e.g. beetroot juice) and is converted to NO in the human body. Results of previous studies indicate vasodilatory, blood pressure-lowering and performance-enhancing effects as well as positive influences on inflammatory processes and oxidative stress following nitrate intake. The hypothesis is that nitrate intake concomitant to training promotes training adaptations and further improves vascular function, blood pressure and physical performance compared to training without nitrate intake.\n\nFor the study, 54 untrained postmenopausal women (with the ages between 45 and 65 years) will be recruited and randomly allocated into two groups. Both groups will undergo 12 weeks of endurance-based exercise training. One group will receive nitrate-rich beetroot juice, and the other nitrate-depleted beetroot juice (as placebo). Vascular function, blood pressure, maximum oxygen uptake, and blood biomarkers for nitrate metabolism, inflammation status and oxidative stress will be examined.\n\nThe anticipated study results will provide new insights into whether nitrate as a 'training adjunct' improves health-promoting training adaptations in women after menopause. The overall aim is to improve the cardiovascular health and performance of middle-aged women and reduce their increased CVD risk.",[67,68,69,70],"Healthy","Menopause","Hypertension","Inflammation",[72,73,74,75,76,77],"Women after menopause","Vascular function","Exercise training responsiveness","Cardiovascular health","Dietary nitrate-nitrite-nitric oxide-pathway","Beetroot juice","2026-06-03",{"date":80,"type":42},"2026-06-05",{"date":82,"type":42},"2025-03-31",{"date":84,"type":20},"2027-03",{"name":48,"class":49},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":59,"sex":15,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":50},"100628039","collagen-peptides-and-cellular-aging-100628039","NCT07456449","Collagen Peptides and Cellular Aging","Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults","Inclusion Criteria:\n\n* Adults aged 50-70 years; both male and female participants are eligible\n* Body mass index (BMI) 25-30 kg\u002Fm²\n* Low to moderate physical activity: not meeting current WHO recommendations (\\\u003C150 minutes\u002Fweek) or ≤2 sessions\u002Fweek structured training\n* Able to live independently and mobile in daily life\n* No regular resistance training within the past 6 months\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases)\n* Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants)\n* Acute infections or surgeries within the last 3 months\n* Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D)\n* Participation in another clinical study within the last 3 months\n* Vegetarian or vegan diet (product contains animal-derived collagen)","50 Years","70 Years",{"count":96,"type":20},125,[23],"The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease).\n\nMain questions it aims to answer are:\n\nDoes six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health?\n\nResearchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers.\n\nParticipants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation\u002Fredox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality.",[100,101,102],"Longevity","Healthy Aging","Biological Ageing",[104,105,106,107,108,109],"Aging","Collagen","Supplements","Patient Care","Healthspan","Cellular aging","2026-04-28",{"date":112,"type":42},"2026-05-05",{"date":114,"type":42},"2026-04-22",{"date":116,"type":20},"2028-08",{"name":48,"class":49},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":59,"sex":15,"minAge":17,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":21,"phases":128,"briefSummary":129,"conditions":130,"keywords":139,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":50},"100628795","l-serine-and-strength-training-in-the-elderly-100628795","NCT07466290","L-serine and Strength Training in the Elderly","AAAging","Inclusion Criteria:\n\n* Men and women between the ages of 65 and 85\n* Mini-Mental-State \\>23\n* Independently mobile, without aids (walker, cane, etc.)\n\nExclusion Criteria:\n\n* Chronic diseases that contraindicate medical training therapy\n* Regular strength training (\\>1x\u002Fweek) in the last 6 months before confinement\n* Frailty Index ≥ 3\n* Lack of written consent to test physical performance\n* Regular use of Cortison-containing medications or Antibiotika\n* MR-specific exclusion criteria: claustrophobia, metal equipment or other magnetic Material in or on the body\n* Non-compliance with the study protocol: \\\u003C70% of the planned L-serine administration, \\\u003C70% of the strength training","85 Years",{"count":127,"type":20},126,[23],"This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.\n\nHealthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.\n\nCognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.",[131,100,132,133,134,135,136,137,138],"Brain Health","Cognitive Performance","Strength Training Effects","Healthy Ageing","Ageing","Cognition","Memory","Muscle Strength",[134,140,141,142,143,144,145,137,146,147,148,149,150,151],"Brain ageing","Older adults","L-serine supplementation","Resistance training","Cognitive function","Cognitive ageing","Hippocampus","Magnetic resonance imaging","Electroencephalography","Brain connectivity","Muscle strength","Synaptic plasticity","2026-03-06",{"date":154,"type":42},"2026-03-12",{"date":156,"type":20},"2026-03",{"date":158,"type":20},"2028-12",{"name":48,"class":49},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":50},"100625116","discrimination-of-n2a-and-n2b-by-ebus-tbna-is-a-change-of-the-needle-necessary-100625116","NCT07418450","Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?","Discrimination of N2a and N2b by EBUS-TBNA: is a Needle Change Necessary? - a Prospective Pilot Study","Inclusion Criteria:\n\n* Pulmonary lesion suspicious for lung cancer or histologically confirmed lung cancer\n* indication for mediastinal staging\n\nExclusion Criteria:\n\n\\-",{"count":168,"type":20},30,[23],"During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.",[172],"Lung Cancer (Diagnosis)","2026-02-10",{"date":175,"type":42},"2026-02-18",{"date":177,"type":42},"2025-11-05",{"date":179,"type":20},"2027-05",{"name":48,"class":49},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":59,"sex":15,"minAge":189,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":50},"100538264","night-shift-work-and-biomarkers-of-obesity-risk-in-hospital-and-industry-workers-100538264","NCT06288568","Night Shift Work and Biomarkers of Obesity Risk in Hospital and Industry Workers","Development and Evaluation of Nutritional Strategies to Reduce and Prevent Obesity in Shiftworkers","Shift2Health","Inclusion Criteria shift worker\n\n* Health care sector or industrial shift worker\n* Employed or self-employed\n* 21 years or older\n* ≥ 24 h\u002F week\n* Shift work duration \\> 3 years and currently doing night shifts\n* 4 or more rotating night shifts\u002Fmonth (night shift defined as a work schedule that involves working at least 3 hours between 00:00 and 5:00), at least 2 consecutive nights\u002Fmonth\n\nInclusion criteria controls\n\n* Health care sector or industrial work\n* Employed or self-employed\n* 21 years or older\n* ≥ 24 h\u002F week\n* No night shift or rotating shift work in the last 5 years\n* No history of night shift or rotating shift work for more than 5 years\n\nExclusion Criteria shift worker and controls:\n\n* Pregnancy\n* Lactation period\n* BMI of 40 kg\u002Fm2 or above\n* Present treatment of a disease e.g. cancer radio- or chemotherapy\n* Chronic diseases if in an ongoing therapy but not after a remission (renal failure, active hepatitis, cirrhosis, myocardial infarction, chronic obstructive pulmonary disease and cancer)\n* Immunodeficiency syndrome, any auto-immune or auto-inflammatory diseases (e.g. type-1 diabetes, multiple sclerosis, lupus, rheumatoid arthritis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever)\n* Bariatric surgery\n* Antibiotics in the last month","21 Years",{"count":191,"type":20},1000,"OBSERVATIONAL","Shift work is a well-known risk factor for the development of overweight and obesity, which may lead to downstream effects such as increased risk of cardiometabolic diseases and cancer. However, the biological and behavioral mechanisms underlying the obesogenicity of night shift work are not well understood. Population-based mechanistic studies in real life shift workers are needed to address how night shift work impacts metabolic health.\n\nThe investigators aim to characterize the behavioural, environmental, and biological mechanisms and pathways for the association of night shift work and obesity across Europe.\n\nThe investigators will conduct a cross sectional study in 5 European countries (Austria, Denmark, Germany, Netherlands and Poland) and recruit 1000 rotating night shift workers and day workers (200\u002Fcountry) from the health sector and different industries. Night and day workers will be age-frequency (3 age groups), gender and (where possible) working tasks matched. Participants will complete online questionnaires and report their diet habits in a mobile app. Body composition, dietary behavior and sensory preferences will be tested. Biologic specimens (blood, urine, saliva, hair and feces) will be collected at the workplace on a day where participants are working on a day shift (or a day off). In a subsample (Austria and Netherlands) shift workers will provide biological samples (spot blood, urine and saliva) both on a day shift and on a night shift. Biomarkers including hormones, cellular immunity and inflammation, parameters linked to gut health and metabolism of fat and sugar, appetite, oxidative stress, metabolomics and microbiota will be measured. The investigators hypothesize that compared to day workers, night shift workers will experience disrupted levels of pre-obesity markers. Higher circadian disruption, sleep disruption and mistimed eating patterns workers will be associated with more disrupted biomarker profiles. Among rotating shift workers, night shift will be associated with acute disrupted melatonin production, metabolomic profiles and composition of oral microbiota compared to a day shift.",[195,196,197],"Obesity","Shift-work Disorder","Circadian Rhythm Disorders","2025-09-05",{"date":200,"type":42},"2025-09-08",{"date":202,"type":42},"2024-04-01",{"date":204,"type":20},"2028-05-31",{"name":48,"class":49},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":50},"100573347","hop-compounds-on-the-immune-system-in-overweight-people-100573347","NCT06745102","Hop Compounds on the Immune System in Overweight People","Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System in Overweight People With the Onset of Metabolic Diseases","ÜG","Inclusion Criteria:\n\n* BMI 25 - 29,9 kg\u002Fm²\n\nas well as one or more of the following incipient metabolic diseases:\n\n* pre-diabetes (fasting blood glucose 100-125 mg\u002FdL),\n* fatty liver (grade 1-3),\n* high-normal blood pressure to mild hypertension (grade 1, systolic 140-159 mmHg)\n\nExclusion Criteria:\n\n* History of diseases that could falsify the study results\n* inflammatory bowel diseases\n* malignant diseases of the gastrointestinal tract\n* food allergies\n* malabsorption\n* kidney or liver disease (except simple fatty liver)\n* symptomatic heart failure\n* Taking medication to treat these diseases\n* Consumption of special diets (e.g. vegan, gluten-free)\n* Pregnancy","75 Years",{"count":216,"type":20},24,[23],"The aim of the present study is to determine the effect of Iso-alpha Acids and Xanthohumol from hops on the immune response in overweight participants.",[220],"Inflammatory Response","2025-04-10",{"date":223,"type":42},"2025-04-15",{"date":225,"type":42},"2024-02-01",{"date":227,"type":20},"2025-12-30",{"name":48,"class":49},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":59,"sex":15,"minAge":16,"maxAge":94,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":246,"locationsCount":50},"100538117","xanthohumol-and-viral-infections-xl-100538117","NCT06286657","Xanthohumol and Viral Infections (XL)","Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans","Inclusion Criteria:\n\n* healthy\n* BMI \\>18 kg\u002Fm² or \\\u003C 28kg\u002Fm²\n\nExclusion Criteria:\n\n* food intolerances\n* food allergies\n* chronic inflammatory diseases\n* metabolic diseases\n* viral or bacterial infections within the last 3 weeks of inclusion\n* intake of immunosuppressive medication\n* severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months\n* influenza infection in the \"current\" flu season",{"count":237,"type":20},100,[23],"The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.",[241],"Infection Viral",{"date":223,"type":42},{"date":244,"type":42},"2023-08-01",{"date":227,"type":20},{"name":48,"class":49},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":59,"sex":15,"minAge":16,"maxAge":94,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":50},"100538116","hop-compounds-on-the-immune-system-vh-100538116","NCT06286644","Hop Compounds on the Immune System (VH)","Effect of Iso-alpha Acids and Xanthohumol on the Human Immune System","Inclusion Criteria:\n\n* healthy\n* BMI: \\>18,5 kg\u002Fm² or \\\u003C30 kg\u002Fm²\n\nExclusion Criteria:\n\n* food intolerances\n* food allergies\n* chronic inflammatory diseases\n* metabolic diseases\n* viral or bacterial infections within the last 3 weeks of inclusion\n* intake of immunosuppressive medication",{"count":255,"type":20},14,[23],"The aim of the present study is to determine the effect of Iso-alpha-Acids and Xanthohumol from hops on the immune response of healthy participants over a timeframe of 6 hours.",[220],{"date":223,"type":42},{"date":261,"type":42},"2022-05-30",{"date":227,"type":20},{"name":48,"class":49},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":59,"sex":15,"minAge":16,"maxAge":94,"enrollmentInfo":271,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":273,"conditions":274,"keywords":280,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":50},"100548631","probing-the-efficacy-of-commercial-stage-storage-buffers-and-evaluating-gut-metaproteome-variability-between-individuals-100548631","NCT06423508","PRObing The Efficacy of Commercial Stage Storage Buffers and Evaluating Gut Metaproteome Variability Between Individuals","PROTEGI","Inclusion Criteria:\n\n* agreeing to participate after signing the informed consent form and\n* being 18-70 years old.\n\nExclusion Criteria:\n\n* take antibiotics during the previous 1 month\n* had undergone gastrointestinal surgery",{"count":272,"type":20},52,"The study aims to assess the effectiveness of various commercial and non-hazardous buffers for the storage of human gut fecal samples over time. This evaluation will be conducted by comparing the performance of these buffers against directly frozen samples using metaproteomic analysis. The study is motivated by the need for standardized protocols for sample preservation in metaproteomic research, particularly focusing on protein preservation in fecal samples. By investigating proteomic, taxonomic, and functional identifications, the research seeks to provide insights into the reliability of these buffers as storage solutions. Additionally, the study plans to explore inter- and intra-individual variabilities at the proteome level by periodically collecting fecal samples from volunteers, complementing existing knowledge in metaproteomics. Overall, the study addresses a critical gap in the field and has the potential to enhance reproducibility and comparability across metaproteomic studies",[275,276,277,278,279],"Gut Microbiome","Buffer","Methodology Study","Fecal Microbiota","Variability",[281,282,283,284,285,286],"storage buffer","fecal samples","human gut microbiome","metaproteomics","intra-individual variability","inter-individual variability","2025-03-24",{"date":289,"type":42},"2025-03-25",{"date":291,"type":42},"2024-12-03",{"date":293,"type":20},"2025-09-30",{"name":48,"class":49},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":310,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100582612","youth-mental-health-recovery-in-the-family-after-inpatient-stay-100582612","NCT06865573","Youth Mental Health Recovery in the Family After Inpatient Stay","Reintegration, Coping, and Care of Families After Inpatient Child and Adolescent Psychiatric Treatment","ReCoVer","Inclusion Criteria:\n\n* 18 years or older\n* primary caregiver of a child or adolescent aged 7-21 years of any gender who received inpatient treatment in a psychiatric institution in Germany, Austria, or Switzerland (min. 24 h stay) within the past month (regardless of the diagnosis or the reason for the treatment, respectively)\n* lived with the child or adolescent in the same household since discharge\n\nExclusion Criteria:\n\n* another caregiver of the same child has already participated in the study\n* insufficient knowledge of German",{"count":304,"type":20},70,"The goal of this longitudinal mixed-methods study is to investigate caregiver strain, family processes and health outcomes after youth psychiatric inpatient treatment. Caregivers of youth who received inpatient treatment for mental health problems will complete a survey at three timepoints (baseline, 3- and 6- month followup) reporting on youth outcomes, caregiver well-being, and family processes. Qualitative interviews on caregivers' challenges, needs, and resources around the return to home care are conducted with a subsample (target n = 10) of participants.\n\nThe main research questions (RQs) are:\n\nRQ 1: Do family processes contribute to youth mental health outcomes after discharge from inpatient treatment? RQ 1a: What family-level risk factors predict youth readmission to inpatient treatment? RQ 1b: Do family processes predict youth mental health trajectories over time? RQ 2: Is there a reciprocal relationship between youth mental health problems and caregiver burden? RQ 2a: Do family processes mediate the association between caregiver burden and youth mental health problems? RQ 3: How do caregivers experience their children's return to home care? RQ 3a: What challenges and needs do caregivers report? RQ 3b: What types of follow-up services do families receive and\u002For have access to? RQ 3c: How do caregivers cope with ongoing difficulties in the post-discharge period?",[307,308,309],"Caregiver Burden","Family Characteristics","Parent-Child Interactions","NOT_YET_RECRUITING","2025-03-12",{"date":313,"type":42},"2025-03-17",{"date":315,"type":20},"2025-05",{"date":317,"type":20},"2026-04",{"name":48,"class":49},""]